Test predicts good MS prognosis
Enlarge image


Test predicts good MS prognosis

12.03.2013 - Elan and Biogen Idec have presented a new test at AAN meeting which identifies JCV infected MS patients with good prognosis.

Whilst Tysabri (natalizumab) is the most effective treatment for relapsing multiple sclerosis, it has also its downsides: the antibody drug increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study presented at the American Academy of Neurology's 65th Annual Meeting in San Diego suggests that early detection of PML may help improve survival and disability levels of MS patients.  

In the study, which was conducted by Irish Elan and Biogen Idec, 319 MS patients were treated with natalizumab and diagnosed with PML. The study compared people who had symptoms of PML at the time of diagnosis to people who had no symptoms of the infection, but who were diagnosed with the disease by brain scans and tests in the spinal fluid for the JC virus. The level of disability for the people in the study was assessed before the PML diagnosis, at the time of diagnosis, and again six months and one year after the diagnosis.  

A total of 21 people had no PML symptoms at the time of their diagnosis, while 298 people did. According to preliminary findings, people without symptoms at diagnosis showed improved survival and less disability than those who had developed symptoms. As of January 1, 2013, all of the 21 people (100%) with no symptoms at the time of PML diagnosis were alive, compared to 77% of the people with symptoms at the time of diagnosis. "These results suggest that the consequences of PML infection can be mitigated by early detection of the disease," said lead investigator Dong-Si.  

In mid-February, US biotech Biogen Idec had bagged full rights to Elan's Multiple Sclerosis blockbuster Tysabri in a US$3.25bn deal. Shortly after the agreement, US investor Royalty Pharma made a take-over bid but the Irish drugmaker is fighting off a possible take-over.



01.12.2015 Almirall is strengthening its dermatology focus with the takeover of Poli Group. Part of the deal are the group’s two pharma companies, German Taurus Pharma GmbH and Swiss Polichem S.A., and Italian Polichem S.r.l., which produces plastics additives.


26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • BIOFRONTERA (D)1.99 EUR6.99%
  • EPIGENOMICS (D)2.80 EUR5.66%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • EVOCUTIS (UK)0.11 GBP-8.33%
  • SARTORIUS (D)246.25 EUR-7.08%


  • PLETHORA (UK)5.50 GBP100.0%
  • GENMAB (DK)910.00 DKK33.8%


  • EPIGENOMICS (D)2.80 EUR-43.4%
  • EVOCUTIS (UK)0.11 GBP-26.7%


  • KARO BIO (S)37.60 SEK5349.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)47.21 EUR263.2%


  • BIOTEST (D)15.71 EUR-80.7%
  • NEOVACS (F)0.78 EUR-76.6%

No liability assumed, Date: 01.12.2015